Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005634 · ClinicalTrials.gov registry record · Phase 1
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00005634: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00005634 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005634, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced primary or metastatic solid tumors that have not responded to previous therapy.
Interventions
- DRUG vorinostat
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-01 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
What the finished NCT00005634 record still lists
NCT00005634 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which vorinostat is the first listed.
NCT00005634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005634 about?
NCT00005634 is a clinical study titled "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced primary or metastatic solid tumors that have not respon...
What is the current status of trial NCT00005634?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-01. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00005634?
The interventions under investigation include: vorinostat (DRUG).
Who is sponsoring clinical trial NCT00005634?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia